Companies
Paradigm Health
an August 2026 partnership with Ochsner Health increased screening capacity by 41% across the US Gulf South, and the company formally responded to FDA's Real-Time Clinical Trials Initiative RFI.
- Country
- United States
US
Coverage
| US | |
|---|---|
| digital-it | ✓ |
Regulatorsfdaema
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| AI clinical-trial patient recruitment | digital-it | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.